Prevalence of Adverse Events to Radiopharmaceuticals from 2007 to 2011

Silberstein, Edward B.

doi:10.2967/jnumed.114.138057

Cited by 28 publications

(21 citation statements)

References 11 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…99m Tc sestamibi also offers a practical advantage over 99m Tc maraciclatide in that it does not require a 45-min wait period post injection. With an excellent safety record and no serious adverse events associated with over 30 years of clinical use [30], 99m Tc sestamibi has essentially become the primary radiotracer used in the majority of MBI studies. Uptake of 99m Tc sestamibi in tumors is primarily dependent on blood flow to the tumor bed and on increased uptake in the mitochondria of the tumor cells [31].…”

Section: Discussionmentioning

confidence: 99%

Comparison of Tc-99m maraciclatide and Tc-99m sestamibi molecular breast imaging in patients with suspected breast cancer

et al. 2017

View full text Add to dashboard Cite

BackgroundMolecular breast imaging (MBI) performed with 99mTc sestamibi has been shown to be a valuable technique for the detection of breast cancer. Alternative radiotracers such as 99mTc maraciclatide may offer improved uptake in breast lesions. The purpose of this study was to compare relative performance of 99mTc sestamibi and 99mTc maraciclatide in patients with suspected breast cancer, using a high-resolution dedicated gamma camera for MBI. Women with breast lesions suspicious for malignancy were recruited to undergo two MBI examinations—one with 99mTc sestamibi and one with 99mTc maraciclatide. A radiologist interpreted MBI studies in a randomized, blinded fashion to assign an assessment score (1–5) and measured lesion size. Lesion-to-background (L/B) ratio was measured with region-of-interest analysis.ResultsAmong 39 analyzable patients, 21 malignant tumors were identified in 21 patients. Eighteen of 21 tumors (86%) were seen on 99mTc sestamibi MBI and 19 of 21 (90%) were seen on 99mTc maraciclatide MBI (p = 1). Tumor extent measured with both radiopharmaceuticals correlated strongly with pathologic size (99mTc sestamibi, r = 0.84; 99mTc maraciclatide, r = 0.81). The L/B ratio in detected breast cancers was similar for the two radiopharmaceuticals: 1.55 ± 0.36 (mean ± S.D.) for 99mTc sestamibi and 1.62 ± 0.37 (mean ± S.D.) for 99mTc maraciclatide (p = 0.53). No correlation was found between the L/B ratio and molecular subtype for 99mTc sestamibi (r s = 0.12, p = 0.63) or 99mTc maraciclatide (r s = −0.12, p = 0.64). Of 20 benign lesions, 10 (50%) were seen on 99mTc sestamibi and 9 of 20 (45%) were seen on 99mTc maraciclatide images (p = 0.1). The average L/B ratio for benign lesions was 1.34 ±0.40 (mean ±S.D.) for 99mTc sestamibi and 1.41 ±0.52 (mean ±S.D.) for 99mTc maraciclatide (p = 0.75). Overall diagnostic performance was similar for both radiopharmaceuticals. AUC from ROC analysis was 0.83 for 99mTc sestamibi and 0.87 for 99mTc maraciclatide (p = 0.64).Conclusions 99mTc maraciclatide offered comparable lesion uptake to 99mTc sestamibi, in both malignant and benign lesions. There was good correlation between lesion extent and uptake measured from both radiopharmaceuticals. 99mTc maraciclatide offered a marginal (but not significant) improvement in sensitivity over 99mTc sestamibi. Our findings did not support an association between the uptake of either radiopharmaceutical and tumor molecular subtype.Trial registrationClinicalTrials.gov, NCT00888589

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of Tc-99m maraciclatide and Tc-99m sestamibi molecular breast imaging in patients with suspected breast cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Unlike radiotracers, RAI has ARs related to its associated radioactivity and not due to an “unanticipated physiologic response to the vehicle (tracer) carrying the radioactivity” (16). The previously reported frequency of ARs to radiopharmaceuticals are 11/100.000 in Europe, 2.3/100.000 in the US, and more recently, 0.8/100.000 in Japan (17,18,19). The figure quoted for the US remains relatively unchanged from the earlier frequency of 2.3/100.000 (20).…”

Section: Introductionmentioning

confidence: 93%

Adverse Reactions to Radioiodine 131I Therapy of Goiter in West African Tertiary Hospital

Onimode

Ejeh²,

Orunmuyi³

2016

Mirt

View full text Add to dashboard Cite

Objective: Radioactive iodine therapy (RAIT) is established as an efficient means of treating toxic goiter (TG) globally. The field of nuclear medicine (NM) still appears novel to many Nigerian clinicians and patients. A culturally embedded dread of radiation may raise ethical and moral concerns about potential adverse effects in the wake of RAIT in our setting. An adverse drug reaction may be described as “a response to a drug which is noxious and unintended, and which occurs at doses normally used in man”. This study therefore, seeks to review adverse reactions (ARs) experienced following RAIT. We would also like to improve patient and physician education about the safety profile of RAIT.Methods:This is a retrospective analysis of all patients who had received RAIT for thyroid disease from August 2006 to June 2015.Results: Forty typical ARs were experienced following 36 therapy sessions (18.65%) with RAIT in 35 patients (21.47%) aged 17-78 years, of which three had multiple sessions for well-differentiated thyroid carcinoma (WDTC).Conclusion: RAIT remains a safe option for the treatment of benign and TG. The experienced ARs are mainly mild to moderate in severity and mostly short-lived. As larger doses of radioactive iodine for WDTC and TG were more commonly associated with ARs, our study suggests that these patients merit stronger prophylactic measures as well as closer monitoring for earlier detection and management of these reactions.

show abstract

“…[102][103][104] This is very favorable when compared with 4%-12% (ie, 1000 times higher) for ionic radiologic contrast media, 1%-3% for nonionic contrast media, 105 and 1.7% for therapeutic drugs. 106 Moreover, reactions to radiopharmaceuticals tend to be mild and self-limiting.…”

Section: Adverse Reactionsmentioning

confidence: 99%

“…110 Very recently, an event has been reported, flushing of the face and trunk, which occurred shortly after administration of 18 F-FDG and lasted less than 2 hours. 102 However, it has been suggested that the incidence of adverse reactions might increase with the use of newer diagnostic and therapeutic radiopharmaceuticals, in part because of hybrid imaging requiring the administration of x-ray or MRI contrast agents. 111 The inadvertent administration of 82 Sr and 85 Sr to patients undergoing myocardial perfusion studies with 82 Rb was discussed earlier.…”

Section: Adverse Reactionsmentioning

confidence: 99%

Pitfalls and Limitations of SPECT, PET, and Therapeutic Radiopharmaceuticals

Ballinger

2015

Seminars in Nuclear Medicine

View full text Add to dashboard Cite

Prevalence of Adverse Events to Radiopharmaceuticals from 2007 to 2011

Cited by 28 publications

References 11 publications

Comparison of Tc-99m maraciclatide and Tc-99m sestamibi molecular breast imaging in patients with suspected breast cancer

Comparison of Tc-99m maraciclatide and Tc-99m sestamibi molecular breast imaging in patients with suspected breast cancer

Adverse Reactions to Radioiodine 131I Therapy of Goiter in West African Tertiary Hospital

Pitfalls and Limitations of SPECT, PET, and Therapeutic Radiopharmaceuticals

Contact Info

Product

Resources

About